الفهرس 
Approach to Thyroid NodulesOnly 14 pages are availabe for public view
 |  | from | 143 |  |  |
| | | from | 143 | | |
Abstract
Background: Thyroid nodules are a common clinical problem. The prevalence of malignancy in thyroid nodules is currently about 5–15%. Optimal prediction of malignancy in nodular thyroid disease is needed to achieve the best medical and surgical intervention. Midkine (MK), a novel heparin-binding growth factor, plays critical roles in a variety of biological phenomena such as carcinogenesis, inflammation/immunity, blood pressure, cellular proliferation, survival, migration of cellular functions, angiogenesis, fibrinolysis, and host defense and tissue protection. Aim of the Work: The aim of this study is to evaluate the value of serum Midkine as a marker of Malignancy in Patients with Nodular Thyroid Disease. Patients and Methods: This comparative study was conducted on 75 subjects with age ranging from 25-80 years selected from outpatient clinic of Internal Medicine and Endocrinology of Ain Shams University Hospital. Results: Serum Midkine level showed a significant increase in cases with malignant thyroid nodules having irregular borders and microcalcifications than in cases with benign thyroid nodules. Conclusion: Serum Midkine might be the indicator of malignant thyroid cytopathology, suggesting that midkine might serve as a novel biomarker in assessment of thyroid nodules. The present study explored the usefulness of midkine as a biomarker in the differentiation between benign and malignant thyroid nodules in samples from serum.